1921
Volume 90, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Cysticercosis is a potentially fatal and preventable neglected parasitic infection caused by the larval form of . Patients with symptomatic disease usually have signs and symptoms of neurocysticercosis, which commonly manifest as seizures or increased intracranial pressure. Although there are many persons living in the United States who emigrated from highly disease-endemic countries and there are foci of autochthonous transmission of the parasite in the United States, little is known about burden and epidemiology of the disease in this country. In addition, despite advances in the diagnosis and management of neurocysticercosis, there remain many unanswered questions. Improving our understanding and management of neurocysticercosis in the United States will require improved surveillance or focused prospective studies in appropriate areas and allocation of resources towards answering some of the key questions discussed in this report.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.13-0724
2014-05-07
2017-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/90/5/805.html?itemId=/content/journals/10.4269/ajtmh.13-0724&mimeType=html&fmt=ahah

References

  1. Ndimubanzi PC, Carabin H, Budke CM, Nguyen H, Qian YJ, Rainwater E, Dickey M, Reynolds S, Stoner JA, , 2010. A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis 4: e870.[Crossref]
  2. Bern C, Garcia HH, Evans C, Gonzalez AE, Verastegui M, Tsang VC, Gilman RH, , 1999. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis 29: 12031209.[Crossref]
  3. Medina MT, Rosas E, Rubio-Donnadieu F, Sotelo J, , 1990. Neurocysticercosis as the main cause of late-onset epilepsy in Mexico. Arch Intern Med 150: 325327.[Crossref]
  4. Garcia HH, Del Brutto OH, Cysticercosis Working Group in Peru, , 2005. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 4: 653661.[Crossref]
  5. Wallin MT, Kurtzke JF, , 2004. Neurocysticercosis in the United States: review of an important emerging infection. Neurology 63: 15591564.[Crossref]
  6. Ong S, Talan DA, Moran GJ, Mower W, Newdow M, Tsang VC, Pinner RW, Group EMINS, , 2002. Neurocysticercosis in radiographically imaged seizure patients in U.S. emergency departments. Emerg Infect Dis 8: 608613.[Crossref]
  7. Garcia HH, Gonzalez AE, Evans CA, Gilman RH, Cysticercosis Working Group in Peru, , 2003. Taenia solium cysticercosis. Lancet 362: 547556.[Crossref]
  8. Garcia HH, Del Brutto OH, , 2003. Imaging findings in neurocysticercosis. Acta Trop 87: 7178.[Crossref]
  9. Carabin H, Ndimubanzi PC, Budke CM, Nguyen H, Qian Y, Cowan LD, Stoner JA, Rainwater E, Dickey M, , 2011. Clinical manifestations associated with neurocysticercosis: a systematic review. PLoS Negl Trop Dis 5: e1152.[Crossref]
  10. Garcia HH, Del Brutto OH, Nash TE, White AC, Jr Tsang VC, Gilman RH, , 2005. New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg 72: 39.
  11. Nash TE, Singh G, White AC, Rajshekhar V, Loeb JA, Proano JV, Takayanagui OM, Gonzalez AE, Butman JA, DeGiorgio C, Del Brutto OH, Delgado-Escueta A, Evans CA, Gilman RH, Martinez SM, Medina MT, Pretell EJ, Teale J, Garcia HH, , 2006. Treatment of neurocysticercosis: current status and future research needs. Neurology 67: 11201127.[Crossref]
  12. Fleury A, Carrillo-Mezo R, Flisser A, Sciutto E, Corona T, , 2011. Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther 9: 123133.[Crossref]
  13. Nash T, , 2012. Edema surrounding calcified intracranial cysticerci: clinical manifestations, natural history, and treatment. Pathog Glob Health 106: 275279.[Crossref]
  14. Nash TE, Pretell EJ, Lescano AG, Bustos JA, Gilman RH, Gonzalez AE, Garcia HH, Cysticercosis Working Group in Peru, , 2008. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol 7: 10991105.[Crossref]
  15. Ooi WW, Wijemanne S, Thomas CB, Quezado M, Brown CR, Nash TE, , 2011. Short report: a calcified Taenia solium granuloma associated with recurrent perilesional edema causing refractory seizures: histopathological features. Am J Trop Med Hyg 85: 460463.[Crossref]
  16. Serpa JA, Graviss EA, Kass JS, White AC, Jr, 2011. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) 90: 8186.[Crossref]
  17. Figueroa JJ, Davis LE, Magalhaes A, , 2011. Extraparenchymal neurocysticercosis in Albuquerque, New Mexico. J Neuroimaging 21: 3843.[Crossref]
  18. Cantu C, Barinagarrementeria F, , 1996. Cerebrovascular complications of neurocysticercosis. Clinical and neuroimaging spectrum. Arch Neurol 53: 233239.[Crossref]
  19. Callacondo D, Garcia HH, Gonzales I, Escalante D, Nash TE, Cysticercosis Working Group in Peru, , 2012. High frequency of spinal involvement in patients with basal subarachnoid neurocysticercosis. Neurology 78: 13941400.[Crossref]
  20. Lerner A, Shiroishi MS, Zee CS, Law M, Go JL, , 2012. Imaging of neurocysticercosis. Neuroimaging Clin N Am 22: 659676.[Crossref]
  21. Feldman M, Plancarte A, Sandoval M, Wilson M, Flisser A, , 1990. Comparison of two assays (EIA and EITB) and two samples (saliva and serum) for the diagnosis of neurocysticercosis. Trans R Soc Trop Med Hyg 84: 559562.[Crossref]
  22. Wilson M, Bryan RT, Fried JA, Ware DA, Schantz PM, Pilcher JB, Tsang VC, , 1991. Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis 164: 10071009.[Crossref]
  23. Rodriguez S, Wilkins P, Dorny P, , 2012. Immunological and molecular diagnosis of cysticercosis. Pathog Glob Health 106: 286298.[Crossref]
  24. Zea-Vera A, Cordova EG, Rodriguez S, Gonzales I, Pretell EJ, Castillo Y, Castro-Suarez S, Gabriel S, Tsang VC, Dorny P, Garcia HH, for the Cysticercosis Working Group in Peru, , 2013. Parasite antigen in serum predicts the presence of viable brain parasites in patients with apparently calcified cysticercosis only. Clin Infect Dis 57: e154e159.[Crossref]
  25. Rodriguez S, Dorny P, Tsang VC, Pretell EJ, Brandt J, Lescano AG, Gonzalez AE, Gilman RH, Garcia HH, Cysticercosis Working Group in Peru, , 2009. Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. J Infect Dis 199: 13451352.[Crossref]
  26. Bustos JA, Rodriguez S, Jimenez JA, Moyano LM, Castillo Y, Ayvar V, Allan JC, Craig PS, Gonzalez AE, Gilman RH, Tsang VC, Garcia HH, Cysticercosis Working Group in Peru, , 2012. Detection of Taenia solium taeniasis coproantigen is an early indicator of treatment failure for taeniasis. Clin Vaccine Immunol 19: 570573.[Crossref]
  27. Guezala MC, Rodriguez S, Zamora H, Garcia HH, Gonzalez AE, Tembo A, Allan JC, Craig PS, , 2009. Development of a species-specific coproantigen ELISA for human Taenia solium taeniasis. Am J Trop Med Hyg 81: 433437.
  28. Allan JC, Wilkins PP, Tsang VC, Craig PS, , 2003. Immunodiagnostic tools for taeniasis. Acta Trop 87: 8793.[Crossref]
  29. Nash TE, Mahanty S, Garcia HH, Cysticercosis Group in Peru, , 2011. Corticosteroid use in neurocysticercosis. Expert Rev Neurother 11: 11751183.[Crossref]
  30. Garcia HH, Gonzalez AE, Gilman RH, , 2011. Cysticercosis of the central nervous system: how should it be managed? Curr Opin Infect Dis 24: 423427.[Crossref]
  31. Rajshekhar V, , 2010. Surgical management of neurocysticercosis. Int J Surg 8: 100104.[Crossref]
  32. Maguire JH, , 2004. Tapeworms and seizures–treatment and prevention. N Engl J Med 350: 215217.[Crossref]
  33. Centers for Disease Control and Prevention, 1992. Locally acquired neurocysticercosis–North Carolina, Massachusetts, and South Carolina, 1989–1991. MMWR Morb Mortal Wkly Rep 41: 14.
  34. Asnis D, Kazakov J, Toronjadze T, Bern C, Garcia HH, McAuliffe I, Bishop H, Lee L, Grossmann R, Garcia MA, Di John D, , 2009. Neurocysticercosis in the infant of a pregnant mother with a tapeworm. Am J Trop Med Hyg 81: 449451.
  35. Daniels TL, Moore TA, , 2006. Neurocysticercosis in Kansas. Ann Intern Med 144: 150152.[Crossref]
  36. Moore AC, Lutwick LI, Schantz PM, Pilcher JB, Wilson M, Hightower AW, Chapnick EK, Abter EI, Grossman JR, Fried JA, , 1995. Seroprevalence of cysticercosis in an Orthodox Jewish community. Am J Trop Med Hyg 53: 439442.
  37. Rosenfeld EA, Byrd SE, Shulman ST, , 1996. Neurocysticercosis among children in Chicago. Clin Infect Dis 23: 262268.[Crossref]
  38. McCormick GF, , 1985. Cysticercosis: review of 230 patients. Bull Clin Neurosci 50: 76101.
  39. Sorvillo FJ, Waterman SH, Richards FO, Schantz PM, , 1992. Cysticercosis surveillance: locally acquired and travel-related infections and detection of intestinal tapeworm carriers in Los Angeles County. Am J Trop Med Hyg 47: 365371.
  40. Schantz PM, Moore AC, Munoz JL, Hartman BJ, Schaefer JA, Aron AM, Persaud D, Sarti E, Wilson M, Flisser A, , 1992. Neurocysticercosis in an Orthodox Jewish community in New York City. N Engl J Med 327: 692695.[Crossref]
  41. Barton Behravesh C, Mayberry LF, Bristol JR, Cardenas VM, Mena KD, Martinez-Ocana J, Flisser A, Snowden KF, , 2008. Population-based survey of taeniasis along the United States–Mexico border. Ann Trop Med Parasitol 102: 325333.[Crossref]
  42. DeGiorgio C, Pietsch-Escueta S, Tsang V, Corral-Leyva G, Ng L, Medina MT, Astudillo S, Padilla N, Leyva P, Martinez L, Noh J, Levine M, del Villasenor R, Sorvillo F, , 2005. Sero-prevalence of Taenia solium cysticercosis and Taenia solium taeniasis in California, USA. Acta Neurol Scand 111: 8488.[Crossref]
  43. Ciesielski S, Seed JR, Estrada J, Wrenn E, , 1993. The seroprevalence of cysticercosis, malaria, and Trypanosoma cruzi among North Carolina migrant farmworkers. Public Health Rep 108: 736741.
  44. Ehnert KL, Roberto RR, Barrett L, Sorvillo FJ, Rutherford GW, 3rd, 1992. Cysticercosis: first 12 months of reporting in California. Bull Pan Am Health Organ 26: 165172.
  45. O'Neal S, Noh J, Wilkins P, Keene W, Lambert W, Anderson J, Compton Luman J, Townes J, , 2011. Taenia solium tapeworm infection, Oregon, 2006–2009. Emerg Infect Dis 17: 10301036.[Crossref]
  46. Townes JM, Hoffmann CJ, Kohn MA, , 2004. Neurocysticercosis in Oregon, 1995–2000. Emerg Infect Dis 10: 508510.[Crossref]
  47. Croker C, Redelings M, Reporter R, Sorvillo F, Mascola L, Wilkins P, , 2012. The impact of neurocysticercosis in california: a review of hospitalized cases. PLoS Negl Trop Dis 6: e1480.[Crossref]
  48. Henneman PL, DeRoos F, Lewis RJ, , 1994. Determining the need for admission in patients with new-onset seizures. Ann Emerg Med 24: 11081114.[Crossref]
  49. del la Garza Y, Graviss EA, Daver NG, Gambarin KJ, Shandera WX, Schantz PM, White AC, Jr, 2005. Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg 73: 766770.
  50. Croker C, Reporter R, Mascola L, , 2010. Use of statewide hospital discharge data to evaluate the economic burden of neurocysticercosis in Los Angeles County (1991–2008). Am J Trop Med Hyg 83: 106110.[Crossref]
  51. Sorvillo FJ, DeGiorgio C, Waterman SH, , 2007. Deaths from cysticercosis, United States. Emerg Infect Dis 13: 230235.[Crossref]
  52. Coyle CM, Mahanty S, Zunt JR, Wallin MT, Cantey PT, White AC, Jr O'Neal SE, Serpa JA, Southern PM, Wilkins P, McCarthy AE, Higgs ES, Nash TE, , 2012. Neurocysticercosis: neglected but not forgotten. PLoS Negl Trop Dis 6: e1500.[Crossref]
  53. Flisser A, Sarti E, Lightowlers M, Schantz P, , 2003. Neurocysticercosis: regional status, epidemiology, impact and control measures in the Americas. Acta Trop 87: 4351.[Crossref]
  54. O'Neal SE, Robbins NM, Townes JM, , 2012. Neurocysticercosis among resettled refugees from Burma. J Travel Med 19: 118121.[Crossref]
  55. O'Neal SE, Townes JM, Wilkins PP, Noh JC, Lee D, Rodriguez S, Garcia HH, Stauffer WM, , 2012. Seroprevalence of antibodies against Taenia solium cysticerci among refugees resettled in United States. Emerg Infect Dis 18: 431438.[Crossref]
  56. Sorvillo F, Wilkins P, Shafir S, Eberhard M, , 2011. Public health implications of cysticercosis acquired in the United States. Emerg Infect Dis 17: 16.[Crossref]
  57. Richards FO, Jr Schantz PM, Ruiz-Tiben E, Sorvillo FJ, , 1985. Cysticercosis in Los Angeles County. JAMA 254: 34443448.[Crossref]
  58. Del Brutto O, , 2012. Neurocysticercosis among international travelers to disease-endemic areas. J Travel Med 19: 112117.[Crossref]
  59. Bobes RJ, Hernandez M, Marquez C, Fragoso G, Garcia E, Parkhouse RM, Harrison LJ, Sciutto E, Fleury A, , 2006. Subarachnoidal and intraventricular human neurocysticercosis: application of an antigen detection assay for the diagnosis and follow-up. Trop Med Int Health 11: 943950.[Crossref]
  60. Deckers N, Dorny P, , 2010. Immunodiagnosis of Taenia solium taeniosis/cysticercosis. Trends Parasitol 26: 137144.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.13-0724
Loading
  • Received : 10 Dec 2013
  • Accepted : 14 Feb 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error